Navigation Links
Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
Date:4/30/2009

SEATTLE, April 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the first quarter ended March 31, 2009, after the close of market on May 7, 2009. The company's earnings conference call will take place May 7, 2009, at 2 p.m. PDT (5 p.m. EDT).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com.

First-Quarter 2009 Earnings Conference Call: 2 p.m. PDT (5 p.m. EDT), May 7, 2009

Trubion will host a conference call and webcast to discuss its financial results in the first quarter, which ended March 31, 2009. The call will be held May 7 at 2 p.m. PDT (5 p.m. EDT). The live event will be available on Trubion's website at http://investors.trubion.com, or by calling (877) 795-3638 or (719) 325-4816. A replay of the discussion will be available from Trubion's website or by calling (888) 203-1112 or (719) 457-0820 and entering 6540657. The telephone replay will be available until midnight, May 14, 2009.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes m
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
2. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
3. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
4. Trubion Announces Presentations at Upcoming Investor Conferences
5. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
8. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
9. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
10. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
11. Trubion Announces Presentations at April/May Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary commercial focus on ... granted a Type C meeting with the U.S. Food ... be held in February 2015.  During this meeting the ...
(Date:12/17/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, announced today its presentation at the ... San Francisco, CA. ... will present on Monday, January 12, 2015, at 9:00 ... webcast live and may be accessed from the "Webcasts ...
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ) ... and investor conference presentations and third,quarter 2008 earnings ... Meeting in Washington D.C. from,October 25 through October ... data in posters and an oral presentation pertaining ...
... Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), ... viral,infections, today announced that updated preliminary data from the first,stage of ...
... product ... development for NewCardio, SANTA CLARA, Calif., ... diagnostic and services company, today,announced Dorin Panescu, PhD, has agreed ... Research and Development, effective,October 20. Dr. Panescu joins NewCardio from ...
Cached Biology Technology:Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call 2Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4Dorin Panescu Named NewCardio's Chief Technical Officer 2Dorin Panescu Named NewCardio's Chief Technical Officer 3Dorin Panescu Named NewCardio's Chief Technical Officer 4
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)... Ariz. , Dec. 2, 2014 As ... hand readers, Inception Technologies is pleased to announce the ... easier for customers to collect the workforce data that ... problems that have been left by existing readers. Many ... user interface, connectivity and modern technology. Older models force ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... Neuherberg, February 10., 2010. Eczema in early childhood ... This is a key finding of a prospective birth ... contributed. In cooperation with colleagues of Ludwig-Maximilians-Universitt (LMU), Technische ... this study followed 5,991 children who were born between ...
... by a top ecological,forecaster says it is harder than ... systems will occur -- a worrisome,finding for scientists trying ... into an irreparable global disaster. "Many scientists are ... natural systems, in hopes of forestalling those changes,or improving ...
... off attacks by Hessian fly larvae by essentially destroying the ... a study by Purdue University and the U.S. Department of ... intestines - were observed in three different feeding situations. Larvae ... given nothing to eat showed no damage to the midgut, ...
Cached Biology News:Eczema in early childhood and psychological problems 2New UC Davis study: Climate 'tipping points' may arrive without warning, says top forecaster 2Resistant wheat goes for the gut to protect against Hessian flies 2